[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100649635":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":32,"locations":41,"responsibleParty":58,"collaborators":62,"id":72,"slug":73,"hasResults":74,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":26,"eligibilityCriteria":78,"healthyVolunteers":74,"sex":79,"minAge":80,"maxAge":81,"enrollmentInfo":82,"targetDuration":26,"studyType":85,"phases":86,"briefSummary":88,"conditions":89,"keywords":91,"overallStatus":44,"whyStopped":26,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":104},{"fullName":5,"class":6},"University of Leeds","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Standard care (tezepelumab)","ACTIVE_COMPARATOR","Tezepelumab administered according to routine clinical practice and the licensed prescribing information for the treatment of severe asthma.",[13],"Drug: Tezepelumab",{"label":15,"type":16,"description":17,"interventionNames":18},"Physical activity promotion plus standard care (tezepelumab)","EXPERIMENTAL","Participants will receive standard care for severe asthma, including tezepelumab administered according to routine clinical practice and the licensed prescribing information, together with a 12-week structured physical activity promotion programme incorporating evidence-based behaviour change techniques to increase and maintain daily physical activity. Participants will undergo study assessments at baseline, 3 months, and 12 months.",[19],"Behavioral: Physical activity promotion",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"BEHAVIORAL","Physical activity promotion","A 12-week structured physical activity promotion programme delivered alongside standard care for severe asthma. The intervention comprises an individual behavioural consultation followed by six online group support sessions delivered every two weeks. It incorporates evidence-based behaviour change techniques, including personalised goal setting, action planning, self-monitoring using the Active10 smartphone application, feedback, problem solving, and relapse prevention, informed by the Capability, Opportunity, Motivation-Behaviour (COM-B) framework to support sustained increases in daily physical activity.",[15],null,{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":26},"DRUG","Tezepelumab","Tezepelumab administered according to the licensed prescribing information and routine clinical practice for the treatment of severe asthma. All participants receive tezepelumab as standard care throughout the study.",[9],[33,38],{"name":34,"role":35,"phone":36,"phoneExt":26,"email":37},"Oliver J Price, PhD","CONTACT","+44(0)113 343 2909","o.price1@leeds.ac.uk",{"name":39,"role":35,"phone":26,"phoneExt":26,"email":40},"Ian J Clifton, MD","i.clifton@nhs.net",[42],{"facility":43,"status":44,"city":45,"state":26,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"Leeds Teaching Hospitals NHS Trust","RECRUITING","Leeds","LS9 7TF","United Kingdom","UK",{"type":50,"coordinates":51},"Point",[52,53],-1.54785,53.79648,{"lat":53,"lon":52},[56,57],{"name":34,"role":35,"phone":26,"phoneExt":26,"email":37},{"name":39,"role":35,"phone":26,"phoneExt":26,"email":40},{"type":59,"investigatorFullName":60,"investigatorTitle":61,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"PRINCIPAL_INVESTIGATOR","Dr Oliver Price","Associate Professor",[63,66,68,70],{"name":64,"class":65},"Hull University Teaching Hospitals NHS Trust","OTHER_GOV",{"name":67,"class":6},"Bradford Institute for Health Research",{"name":69,"class":6},"Mid Yorkshire Teaching NHS Trust",{"name":71,"class":6},"Sheffield Teaching Hospitals NHS Foundation Trust","100649635","physical-activity-promotion-and-clinical-remission-in-severe-asthma-100649635",false,"NCT07735494","Physical Activity Promotion and Clinical Remission in Severe Asthma","Impact of Physical Activity Promotion on Clinical Remission in Adults With Severe Asthma Receiving Tezepelumab: A Multicentre, Open Label, Randomised Controlled Trial","Inclusion Criteria:\n\n* Adults aged 18-70 years.\n* Physician-diagnosed severe asthma.\n* Eligible for tezepelumab according to NICE TA880.\n* History of ≥3 asthma exacerbations requiring oral corticosteroids in the previous 12 months or receiving maintenance oral corticosteroid therapy.\n* Objective confirmation of asthma, including bronchodilator reversibility, bronchial hyperresponsiveness and\u002For variable airflow obstruction, as part of routine clinical assessment.\n* Decision to commence tezepelumab made by the treating multidisciplinary severe asthma team prior to study enrolment.\n* Able and willing to provide written informed consent.\n\nExclusion Criteria:\n\n* Non-asthma respiratory disease that may confound study outcomes (e.g. obstructive sleep apnoea).\n* Pregnancy.\n* Significant non-asthma medical conditions likely to impair physical activity or functional exercise capacity (e.g. acute musculoskeletal injury).\n* Any condition that, in the opinion of the investigator, would make participation unsafe or compromise study completion.","ALL","18 Years","70 Years",{"count":83,"type":84},140,"ESTIMATED","INTERVENTIONAL",[87],"NA","This study will investigate whether a structured physical activity promotion programme, delivered alongside standard treatment with tezepelumab, increases objectively measured physical activity and the proportion of adults with severe asthma achieving clinical remission compared with standard care alone. Although biologic therapies have improved asthma control for many people with severe asthma, many individuals remain physically inactive, experience reduced exercise tolerance, and continue to report symptoms that affect their quality of life. Physical inactivity may represent a modifiable factor that limits the achievement of optimal health outcomes.\n\nAdults with severe asthma who are starting tezepelumab as part of routine clinical care will be randomly assigned to receive either standard care alone or standard care plus a 12-week physical activity promotion programme. The programme includes an individual consultation, group behavioural support sessions, personalised goal setting, self-monitoring using a smartphone application, and strategies to help participants increase and maintain their physical activity levels. Participants will be followed for 12 months.\n\nThe study will primarily assess change in objectively measured daily step count after 3 months. The primary clinical outcome will be the proportion of participants achieving clinical remission after 12 months. Additional outcomes include asthma disease stability, asthma exacerbations, objectively measured physical activity at 12 months and functional exercise capacity. The findings will help determine whether combining physical activity promotion with biologic therapy improves outcomes for adults with severe asthma and could inform future models of routine severe asthma care.",[90],"Severe Asthma",[90,92,29,93,94],"Treatable Traits","Self-management","Behavioural Intervention","2026-08-12",{"date":97,"type":98},"2026-08-17","ACTUAL",{"date":100,"type":98},"2026-07-31",{"date":102,"type":84},"2029-12-01",{"name":5,"class":6},1]